Effect of a hypolipidaemic drug (CH 13,437) on plasma and tissue lipids, and on the intravenous fat tolerance in man.
D000328:Adult; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001842:Bone and Bones / Q000032:analysis; D002784:Cholesterol / Q000097:blood; D005230:Fatty Acids, Nonesterified / Q000378:metabolism; D006003:Glycogen / Q000032:analysis; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D007275:Injections, Intravenous; D050356:Lipid Metabolism; D008055:Lipids / Q000032:analysis / Q000097:blood; D008071:Lipoprotein Lipase / Q000097:blood; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008079:Lipoproteins, VLDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D009132:Muscles / Q000032:analysis; D009255:Nafenopin / Q000627:therapeutic use; D010743:Phospholipids / Q000032:analysis / Q000097:blood; D011422:Propionates / Q000627:therapeutic use*; D013997:Time Factors; D014280:Triglycerides / Q000032:analysis / Q000097:blood / Q000378:metabolism
D000924:Anticholesteremic Agents; D005230:Fatty Acids, Nonesterified; D008055:Lipids; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D010743:Phospholipids; D011422:Propionates; D014280:Triglycerides; D009255:Nafenopin; D006003:Glycogen; D002784:Cholesterol; D008071:Lipoprotein Lipase